About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Lymphoma Clinical Trials in Illinois | 664 Studies

Clinical Trials LymphomaIllinois

Lymphoma Clinical Trials in Illinois

Find 664 clinical trials for lymphoma near Illinois. Connect with research centers in your area.

All Lymphoma trials nationwide All trials in Illinois

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 181-200 of 664 trials

CompletedA Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)This study will compare the safety and effectiveness of PF-05280586 versus rituximab-EU in patients with CD20-positive, low tumor burden follicular lymphoma.NCT02213263·Anaheim, California and 422 others

Lymphoma Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

RecruitingTesting the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell LymphomaThis phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in…NCT04803201·Little Rock, Arkansas and 95 others

CompletedIxabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's LymphomaThis phase II trial is studying how well ixabepilone works in treating patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.NCT00058019·Chicago, Illinois and 1 other

RecruitingTesting Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell LymphomaThis phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell…NCT05976763·Little Rock, Arkansas and 237 others

CompletedRituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS LymphomaRATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.NCT00098774·San Francisco, California and 29 others

CompletedPhase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & LymphomaThe purpose of this research study is to determine the highest and safest dose of the experimental drug veliparib when combined with nivolumab.NCT03061188·Chicago, Illinois

CompletedIntensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic MalignanciesThis is a phase I study using Intensity Modulated Total Marrow Irradiation (IM-TMI) in addition to a chemotherapy regimen in preparation for an allogeneic stem cell transplant for…NCT00988013·Chicago, Illinois

RecruitingTesting the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaThis phase I trial studies the side effects and best dose of mosunetuzumab when given together with polatuzumab vedotin and lenalidomide in treating patients with diffuse large…NCT06015880·Duarte, California and 7 others

CompletedPeripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic CancerRATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy.NCT00006225·Chicago, Illinois

RecruitingA Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and LymphomasThe purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of…NCT04104776·Tampa, Florida and 79 others

CompletedA Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Participants With Indolent Non-Hodgkin LymphomaThis study examined the effects of predefined 2-week duvelisib dose holidays on tumor responses and safety/tolerability.NCT04038359·Fort Myers, Florida and 27 others

CompletedA Safety and Tolerability Study of PCI-24781 in Subjects With CancerThe purpose of this study is to determine the long-term (\> 6 months) safety of PCI 24781 PO in subjects with lymphoma.NCT01149668·Chicago, Illinois and 4 others

CompletedSafety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell LymphomaThe purpose of this study is to test the safety of Iodine-131 Anti-B1 Antibody followed by CHOP and to see what effects it has on patients with previously untreated mantel cell…NCT00022945·Chicago, Illinois and 2 others

CompletedProleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma.The purpose of this study is to determine the safety and effectiveness of combination therapy with Proleukin and Rituxan on patients with intermediate-and high- grade…NCT00045864·Tucson, Arizona and 32 others

CompletedEfficacy and Safety Study of Fostamatinib Tablets to Treat B-cell LymphomaPatients: B-cell lymphoma, refractory, diffuse, nodular, mantle, other Phase I : Two groups of 6 patients, escalating dose tolerability- 28 days Phase II: Three groups of 16…NCT00446095·Los Angeles, California and 10 others

TerminatedGamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell LeukemiaThis phase I/II clinical trial is studying the side effects and best dose of gamma-secretase inhibitor RO4929097 and to see how well it works in treating young patients with…NCT01088763·Palo Alto, California and 11 others

TerminatedNovel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular LymphomaFirst study, at multiple clinical centers, exploring the effects of different combinations of compounds (CC-122, CC-223 ,CC-292 and rituximab) to treat Diffuse Large B Cell…NCT02031419·Stanford, California and 15 others

CompletedA Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological MalignanciesTo assess safety and tolerability, describe the dose-limiting toxicities, determine the maximum tolerated dose (MTD) or the highest protocol-defined dose (maximum administered…NCT03106428·Los Angeles, California and 13 others

CompletedThalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaPhase II trial to study the effectiveness of thalidomide in treating patients who have relapsed or refractory low-grade non-Hodgkin's lymphoma.NCT00022581·Chicago, Illinois

Active not recruitingStudying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or LymphomaThis phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with…NCT05602194·Birmingham, Alabama and 227 others

PreviousPage 10 of 34Next

Other Conditions in Illinois

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia